Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total Liver Disease Franchise Product Sales by Year
Total Liver Disease Franchise Product Sales — Rest of World sales ($M) ($M)
Gilead Sciences Total Liver Disease Franchise Product Sales: $927M in FY2025, up 5.8% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Liver Disease Franchise Product Sales — Rest of World sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 927 | +5.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 876 | +2.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 852 | +2.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 833 | -8.5% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 910 | – | Form 10-K (filed 2024-02-23) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total Liver Disease Franchise Product Sales ($M), annual FY2021–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-total-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.